These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38548216)

  • 1. Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma.
    Shu M; Huang L; Chen Y; Wang Y; Xie Z; Li S; Zhou J; Wei L; Fu T; Liu B; Chen H; Tang K; Ke Z
    Cancer Lett; 2024 Jul; 593():216835. PubMed ID: 38548216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
    Dong M; Yang Z; Li X; Zhang Z; Yin A
    Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
    Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
    Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
    Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
    BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
    Zhong M; Jiang Q; Jin R
    IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
    Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
    Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.
    Cai Q; He B; Xie H; Zhang P; Peng X; Zhang Y; Zhao Z; Wang X
    Cancer Med; 2020 Oct; 9(20):7488-7502. PubMed ID: 32860318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes.
    Zheng Z; Deng W; Yang J
    Biomed Res Int; 2020; 2020():8832739. PubMed ID: 33490259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
    Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
    J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Cell Death Index for Lung Adenocarcinoma: A Comprehensive Transcriptome-Based Analysis of Twelve Programmed Cell Death Pattern Genes.
    Chen F; Ma J; Hu S; Wu C; Chen S; Lin J
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):135. PubMed ID: 38682187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a four-gene panel predicting overall survival for lung adenocarcinoma.
    Li C; Long Q; Zhang D; Li J; Zhang X
    BMC Cancer; 2020 Dec; 20(1):1198. PubMed ID: 33287749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.